Alaunos Therapeutics (TCRT) 10-Q 9 Nov 18 2018 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2018	Oct. 31, 2018
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q3
Trading Symbol	ZIOP
Entity Registrant Name	ZIOPHARM ONCOLOGY INC
Entity Central Index Key	1,107,421
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Emerging Growth Company	false
Entity Small Business	false
Entity Common Stock, Shares Outstanding		142,379,770

BALANCE SHEETS

BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 31,728	$ 70,946
Receivables	1,021	19
Prepaid expenses and other current assets	14,412	19,818
Total current assets	47,161	90,783
Property and equipment, net	1,344	1,211
Deposits	128	128
Other non-current assets	18,168	13,484
Total assets	66,801	105,606
Current liabilities:
Accounts payable	1,269	4,417
Accrued expenses	9,377	9,909
Contract liability - current portion	49,513	6,389
Deferred rent - current portion	24	141
Total current liabilities	60,183	20,856
Contract liability, net of current portion		35,139
Deferred rent, net of current portion	6	1
Derivative liabilities	2,597	2,424
Total liabilities	62,786	58,420
Commitments and contingencies (Note 6)
Preferred stock, $0.001 par value, 30,000,000 shares authorized
Stockholders' deficit:
Common stock, $0.001 par value; 250,000,000 shares authorized; 142,379,770 and 142,658,037 shares issued and outstanding at September 30, 2018 and December 31, 2017, respectively	142	143
Additional paid-in capital	604,653	615,493
Accumulated deficit	(761,209)	(712,442)
Total stockholders' deficit	(156,414)	(96,806)
Total liabilities and stockholders' deficit	66,801	105,606
Series 1 Preferred Stock
Current liabilities:
Series 1 preferred stock, $1,200 stated value; 250,000 designated; 130,849 and 119,644 shares issued and outstanding at September 30, 2018 and December 31, 2017, respectively; liquidation value of $157.0 million and $143.6 million at September 30, 2018 and December 31, 2017, respectively	$ 160,429	$ 143,992

BALANCE SHEETS (Parenthetical)

BALANCE SHEETS (Parenthetical) - USD ($) $ in Millions	Sep. 30, 2018	Dec. 31, 2017
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	30,000,000	30,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	142,379,770	142,658,037
Common stock, shares outstanding	142,379,770	142,658,037
Series 1 Preferred Stock
Preferred stock, stated value	$ 1,200	$ 1,200
Preferred stock, shares authorized	250,000	250,000
Preferred stock, shares issued	130,849	119,644
Preferred stock, shares outstanding	130,849	119,644
Preferred stock, liquidation preference	$ 157	$ 143.6

STATEMENTS OF OPERATIONS

STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Income Statement [Abstract]
Collaboration revenue		$ 1,598	$ 146	$ 4,792
Operating expenses:
Research and development	$ 8,263	11,105	25,935	33,903
General and administrative	4,307	3,571	15,355	10,946
Total operating expenses	12,570	14,676	41,290	44,849
Loss from operations	(12,570)	(13,078)	(41,144)	(40,057)
Other income (expense), net	150	175	462	299
Change in fair value of derivative liabilities	(165)	202	46	(1,292)
Net loss	(12,585)	(12,701)	(40,636)	(41,050)
Preferred stock dividends	(6,074)	(4,903)	(16,656)	(13,939)
Net loss applicable to common stockholders	$ (18,659)	$ (17,604)	$ (57,292)	$ (54,989)
Basic and diluted net loss per share	$ (0.13)	$ (0.13)	$ (0.41)	$ (0.41)
Weighted average common shares outstanding used to compute basic and diluted net loss per share	141,185,404	140,632,297	141,020,025	135,689,364

STATEMENTS OF CHANGES IN PREFER

STATEMENTS OF CHANGES IN PREFERRED STOCK AND STOCKHOLDERS' DEFICIT - 9 months ended Sep. 30, 2018 - USD ($) $ in Thousands	Total	Common Stock	Additional Paid In Capital Common Stock	Accumulated Deficit	Series 1 Preferred Stock - Mezzanine
Balance at Dec. 31, 2017	$ (96,806)	$ 143	$ 615,493	$ (712,442)	$ 143,992
Balance (in shares) at Dec. 31, 2017		142,658,037			119,644
Adjustment for implementation of ASU No. 2014-09, Revenue from Contracts with Customers	(8,131)			(8,131)
Stock-based compensation	6,850		6,850
Exercise of employee stock options	$ 240		240
Exercise of employee stock options (Share)	104,167	104,166
Cancelled restricted common stock	$ 0	$ 0	0	0	$ 0
Cancelled restricted common stock (shares)		(70,867)
Repurchase of restricted common stock	(1,275)	$ (1)	(1,274)
Repurchase of restricted common stock (shares)		(311,566)
Preferred stock dividends					$ 16,437
Preferred stock dividends	(16,656)		(16,656)
Preferred stock dividends (shares)					11,205
Net loss	(40,636)			(40,636)
Balance at Sep. 30, 2018	$ (156,414)	$ 142	$ 604,653	$ (761,209)	$ 160,429
Balance (in shares) at Sep. 30, 2018		142,379,770			130,849

STATEMENTS OF CASH FLOWS

STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Cash flows from operating activities:
Net loss	$ (40,636)	$ (41,050)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	412	259
Stock-based compensation	6,850	6,165
Change in fair value of derivative liabilities	(46)	1,292
(Increase) decrease in:
Receivables	(1,002)	8
Prepaid expenses and other current assets	5,406	(6,660)
Other noncurrent assets	(4,684)	(3)
Increase (decrease) in:
Accounts payable	(3,148)	1,368
Accrued expenses	(532)	1,002
Contract liabilities	(146)	(4,792)
Deferred rent	(112)	(102)
Net cash used in operating activities	(37,638)	(42,513)
Cash flows from investing activities:
Purchases of property and equipment	(545)	(461)
Net cash used in investing activities	(545)	(461)
Cash flows from financing activities:
Proceeds from exercise of stock options	240	99
Repurchase of restricted common stock	(1,275)	(1,042)
Proceeds from issuance of common stock, net		47,270
Net cash provided by (used in) financing activities	(1,035)	46,327
Net increase (decrease) in cash, cash equivalents, and restricted cash	(39,218)	3,353
Cash, cash equivalents, and restricted cash, beginning of period	71,335	81,441
Cash, cash equivalents, and restricted cash, end of period	32,117	84,794
Supplementary disclosure of cash flow information:
Cash paid for interest	0	0
Cash paid for income taxes	0	0
Series 1 Preferred Stock
Supplementary disclosure of noncash investing and financing activities:
Payment of dividends in preferred stock	$ 16,656	$ 13,939

Business

Business	9 Months Ended
	Sep. 30, 2018
Accounting Policies [Abstract]
Business	1. Business Overview ZIOPHARM Oncology, Inc., which is referred to herein as “Ziopharm,” the “Company,” or “we”, is a biopharmaceutical company seeking to develop, acquire, and commercialize, on its own or with partners, a diverse portfolio of immuno-oncology therapies. The Company’s operations to date have consisted primarily of raising capital and conducting research and development. The Company’s fiscal year ends on December 31. The Company has operated at a loss since its inception in 2003 and has minimal revenues. The Company anticipates that losses will continue for the foreseeable future. At September 30, 2018, the Company’s accumulated deficit was approximately $761.2 million. Given its current development plans, the Company anticipates cash resources will be sufficient to fund operations into the second quarter of 2019. The Company’s ability to continue operations after its current cash resources are exhausted depends on its ability to obtain additional financing in the near term or to achieve profitable operations, as to which no assurances can be given. Cash requirements may vary materially from those currently planned because of changes in the Company’s focus and direction of its research and development programs, competitive and technical advances, patent developments, regulatory changes or other developments. Additional financing will be required to continue operations after the Company exhausts its current cash resources and to continue its long-term plans for clinical trials and new product development. As of September 30, 2018, the Company had approximately $31.7 million of cash and cash equivalents. Given its development plans, the Company anticipates cash resources will be sufficient to fund its operations into the second quarter of 2019 and the Company has no committed sources of additional capital. Based on the forecast, management determined that there is substantial doubt regarding our ability to continue as a going concern. The forecast of cash resources is forward-looking information that involves risks and uncertainties, and the actual amount of the Company’s expenses could vary materially and adversely as a result of a number of factors. The Company has based its estimates on assumptions that may prove to be wrong, and the Company’s expenses could prove to be significantly higher than currently anticipated. Management does not know whether additional financing will be available on terms favorable or acceptable to the Company when needed, if at all. If adequate additional funds are not available when required, or if the Company is unsuccessful in entering into partnership agreements for further development of its products, management may need to curtail development efforts. Basis of Presentation The accompanying unaudited interim financial statements have been prepared in accordance with the instructions to Form 10-Q It is management’s opinion that the accompanying unaudited interim financial statements reflect all adjustments (which are normal and recurring) that are necessary for a fair statement of the results for the interim periods. The unaudited interim financial statements should be read in conjunction with the audited financial statements and the notes thereto for the year ended December 31, 2017, included in the Company’s Annual Report on Form 10-K 10-K. The year-end The results disclosed in the statements of operations for the three and nine months ended September 30, 2018 are not necessarily indicative of the results to be expected for the full fiscal year. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Although the Company regularly assesses these estimates, actual results could differ from those estimates. Changes in estimates are recorded in the period in which they become known. The Company’s most significant estimates and judgments used in the preparation of its financial statements are: • Clinical trial expenses; • Collaboration agreements and revenue recognition; • Fair value measurements of stock based compensation and Series 1 preferred stock; and • Income taxes Subsequent Events The Company evaluated all events and transactions that occurred after the balance sheet date through the date of this filing. Except as disclosed below, the Company did not have any material subsequent events that impacted its financial statements or disclosures. On October 5, 2018, the Company entered into an exclusive license agreement, or the License Agreement, with Precigen, Inc., or Precigen, a wholly owned subsidiary of Intrexon Corporation, or Intrexon. As between the Company and Precigen, the terms of the License Agreement replace the terms of: (a) that certain Exclusive Channel Partner Agreement by and between the Company and Intrexon, dated January 6, 2011, as amended by the First Amendment to Exclusive Channel Partner Agreement effective September 13, 2011, the Second Amendment to the Exclusive Channel Partner Agreement effective March 27, 2015, and the Third Amendment to Exclusive Channel Partner Agreement effective June 29, 2016, which was subsequently assigned by Intrexon to Precigen; (b) certain rights and obligations pursuant to that certain License and Collaboration Agreement effective March 27, 2015 between the Company, Intrexon and ARES TRADING Trading S.A., or Ares Trading, a subsidiary of Merck KGaA, or Merck, as assigned by Intrexon to Precigen, or the Ares Trading Agreement; (c) that certain License Agreement between the Company, Intrexon and The University of Texas M.D. Anderson Cancer Center, or MD Anderson, with an effective date of January 13, 2015, or the MD Anderson License, which was subsequently assigned by Intrexon and assumed by Precigen effective as of January 1, 2018; and (d) that certain Research and Development Agreement between the Company, Intrexon and MD Anderson with an effective date of August 17, 2015, or the Research and Development Agreement, and any amendments or statements of work thereto. Pursuant to the terms of the License Agreement, Precigen has granted the Company an exclusive, worldwide, royalty-bearing, sub-licensable ® IL-12 (iii) T-cell sub-licensable Sleeping Beauty The Company will be solely responsible for all aspects of the research, development and commercialization of the exclusively licensed products for the treatment of cancer. The Company is required to use commercially reasonable efforts to develop and commercialize IL-12 two-year Precigen has also granted the Company an exclusive, worldwide, royalty-bearing, sub-licensable IL-12 IL-12 Precigen will retain rights to research, develop and commercialize CAR products for all other targets, subject to the rights of Merck to pursue such targets under the Ares Trading Agreement. In addition, Precigen may research, develop and commercialize products for the treatment of cancer outside of the products exclusively licensed to the Company. In consideration of the licenses and other rights granted by Precigen, the Company will pay Precigen an annual license fee of $100 thousand and has agreed to reimburse Precigen for certain historical costs of the licensed programs up to $1.0 million, payable quarterly. The Company will make milestone payments totaling up to an additional $52.5 million for each exclusively licensed program upon the initiation of later stage clinical trials and upon the approval of exclusively licensed products in various jurisdictions. In addition, the Company will pay Precigen tiered royalties ranging from low-single IL-12 low-single mid-single The Company is responsible for all development costs associated with each of the licensed products, other than Gorilla IL-12 IL-12 Precigen will pay the Company royalties ranging from low-single mid-single In consideration of the Company entering into the License Agreement, Intrexon has forfeited and returned to the Company all shares of the Company’s Series 1 Preferred Stock held by or payable to Intrexon as of the date of the License Agreement. In connection with the transaction, the Company incurred approximately $7.0 million of transaction advisory costs with a third-party vendor. Of that amount, approximately $1.0 million was expensed during the three months ended June 30, 2018 and approximately $0.3 million during the three months ended September 30, 2018. The remaining balance of advisory fees is due upon closing of the transaction.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2018
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies The Company’s significant accounting policies were identified in the Company’s Form 10-K. 10-K New Accounting Pronouncements In February 2016, the FASB issued ASU No. 2016-02, Leases 2016-02. Leases In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows: Restricted Cash 2016-18. beginning-of-period end-of-period 2016-18 2016-18, September 30, 2018 2017 (in thousands) Cash and cash equivalents $ 31,728 $ 84,406 Restricted cash included in prepaid expenses and other current assets 389 — Restricted cash included in other non-current — 388 Total cash, cash equivalents, and restricted cash shown in the statement of cash flows $ 32,117 $ 84,794 In August 2018, the FASB issued ASU No. 2018-03, Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement 2018-03. In June 2018, the FASB issued ASU No. 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting 2018-07.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2018
Fair Value Disclosures [Abstract]
Fair Value Measurements	3. Fair Value Measurements The Company accounts for its financial assets and liabilities using fair value measurements. The authoritative accounting guidance defines fair value, establishes a framework for measuring fair value under generally accepted accounting principles and enhances disclosures about fair value measurements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value as follows: • Level 1—Quoted prices in active markets for identical assets or liabilities. • Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. • Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Assets and liabilities measured at fair value on a recurring basis as of September 30, 2018 and December 31, 2017 were as follows: ($ in thousands) Fair Value Measurements at Reporting Date Using Description Balance as of Quoted Prices in Significant Other Significant Assets: Cash equivalents $ 30,305 $ 30,305 $ — $ — Liabilities: Derivative liabilities $ (2,597 ) $ — $ — $ (2,597 ) ($ in thousands) Fair Value Measurements at Reporting Date Using Description Balance as of Quoted Prices in Significant Other Significant Assets: Cash equivalents $ 66,156 $ 66,156 $ — $ — Liabilities: Derivative liabilities $ (2,424 ) $ — $ — $ (2,424 ) The cash equivalents represent deposits in a short term United States treasury money market mutual fund quoted in an active market and classified as a Level 1 asset. As discussed further in Notes 6, 7, and 9, the Company issued Intrexon 100,000 shares of the Company’s Series 1 preferred stock, a class of preferred stock authorized by the Company’s board of directors, in consideration of the parties entering into a Third Amendment to Exclusive Channel Partner Agreement, or the 2016 ECP Amendment, amending the existing Exclusive Channel Partner Agreement, effective January 6, 2011 and as amended to date, which the Company refers to as the Channel Agreement, and an Amendment to Exclusive Channel Collaboration Agreement, or the 2016 GvHD Amendment, amending the existing Exclusive Channel Collaboration Agreement, effective September 28, 2015, which the Company refers to as the GvHD Agreement. The Series 1 preferred stock are financial liabilities that consist of a conversion option and a redemption feature and are classified as a Level 3 asset. There were no transfers between asset classes during the three and nine months ended September 30, 2018. At June 30, 2016, the Company’s Series 1 preferred stock was valued using a probability-weighted approach and a Monte Carlo simulation model. Additionally, the monthly dividends issued on the outstanding Series 1 preferred stock are valued using the same probability-weighted approach and a Monte Carlo simulation model. However, there is no adjustment or further revaluation after the initial valuation on the Series 1 preferred stock other than required periodic dividends. The Company’s Level 3 financial liabilities consist of a conversion option and a redemption feature associated with the Company’s Series 1 preferred stock issued to Intrexon that have been bifurcated from the Series 1 preferred stock and are accounted for as derivative liabilities at fair value. The preferred stock derivative liabilities were valued using a probability-weighted approach and a Monte Carlo simulation model. The fair value of the embedded derivatives was estimated using the “with” and “without” method where the preferred stock was first valued with all of its features (“with” scenario) and then without derivatives subject to the valuation analysis (“without” scenario). The fair value of the derivatives was then estimated as the difference between the fair value of the preferred stock in the “with” scenario and the preferred stock in the “without” scenario. See Note 6 for additional disclosures on the 2016 ECP Amendment and 2016 GvHD Amendments and Note 9 for additional disclosure on the rights and preferences of the Series 1 preferred stock and valuation methodology. As discussed in Note 1, in consideration of the Company entering into the License Agreement, Intrexon forfeited and returned to the Company all shares of the Company’s Series 1 Preferred Stock held by or payable to Intrexon as of the date of the License Agreement. No shares of Series 1 Preferred Stock are currently outstanding as of the filing date of this Quarterly Report.

Net Loss per Share

Net Loss per Share	9 Months Ended
	Sep. 30, 2018
Earnings Per Share [Abstract]
Net Loss per Share	4. Net Loss per Share Basic net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding for the period. The Company’s potentially dilutive shares, which include outstanding common stock options, unvested restricted stock and preferred stock, have not been included in the computation of diluted net loss per share for any of the periods presented as the result would be anti-dilutive. Such potentially dilutive shares of common stock at September 30, 2018 and 2017 consisted of the following: September 30, 2018 2017 Stock options 4,569,468 4,122,335 Unvested restricted stock 1,164,352 1,330,492 Preferred stock 52,583,921 22,398,582 58,317,741 27,851,409 The Series 1 preferred stock automatically converts into shares of common stock upon the date the first approval in the United States of (i) a Ziopharm Product, as defined in and developed under the Channel Agreement, or (ii) a Product, as defined in and developed under the GvHD Agreement, or (iii) a Product as defined in and developed under the Ares Trading Agreement is publicly announced. Assuming a conversion event date of September 30, 2018, the Series 1 preferred stock would convert into 52,583,921 shares of common stock using the greater of (i) the volume weighted average closing price of the Company’s Common Stock as reported by the Nasdaq Stock Market, LLC over the previous 20 trading days ending on the conversion event date or (ii) $1.00 per share. See Note 6 and Note 9 for additional disclosure regarding the 2016 ECP Amendment and 2016 GvHD Amendment, valuation methodology and significant assumptions. As discussed in Note 1, in consideration of the Company entering into the License Agreement, Intrexon forfeited and returned to the Company all shares of the Company’s Series 1 Preferred Stock held by or payable to Intrexon as of the date of the License Agreement. No shares of Series 1 Preferred Stock are currently outstanding as of the filing date of this Quarterly Report.

Revenue Recognition

Revenue Recognition	9 Months Ended
	Sep. 30, 2018
Revenue from Contract with Customer [Abstract]
Revenue Recognition	5. Revenue Recognition The Company adopted Accounting Standards Codification, or ASC Topic 606, Revenue from Contracts with Customers The Company primarily generates revenue through collaboration arrangements with strategic partners for the development and commercialization of product candidates. Commencing January 1, 2018, the Company recognizes revenue in accordance with ASC 606. The core principle of ASC 606 is that an entity should recognize revenue to depict the transfer of promised goods and/or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and/or services. To determine the appropriate amount of revenue to be recognized for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following steps: (i) identify the contract(s) with the customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract and (v) recognize revenue when (or as) each performance obligation is satisfied. The Company recognizes collaboration revenue under certain of the Company’s license or collaboration agreements that are within the scope of ASC 606. The Company’s contracts with customers typically include promises related to licenses to intellectual property, research and development services and options to purchase additional goods and/or services. If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, up-front non-refundable, up-front The terms of the Company’s arrangements with customers typically include the payment of one or more of the following: (i) non-refundable, up-front catch-up The Company allocates the transaction price to each performance obligation identified in the contract on a relative standalone selling price basis. However, certain components of variable consideration are allocated specifically to one or more particular performance obligations in a contact to the extent both of the following criteria are met: (i) the terms of the payment relate specifically to the efforts to satisfy the performance obligation or transfer the distinct good or service and (ii) allocating the variable amount of consideration entirely to the performance obligation or the distinct good or service is consistent with the allocation objective of the standard whereby the amount allocated depicts the amount of consideration to which the entity expects to be entitled in exchange for transferring the promised goods or services. The Company develops assumptions that require judgement to determine the standalone selling price for each performance obligation identified in each contract. The key assumptions utilized in determining the standalone selling price for each performance obligation may include forecasted revenues, development timelines, estimated research and development costs, discount rates, likelihood of exercise and probabilities of technical and regulatory success. Revenue is recognized based on the amount of the transaction price that is allocated to each respective performance obligation when or as the performance obligation is satisfied by transferring a promised good and/or service to the customer. For performance obligations that are satisfied over time, the Company recognizes revenue by measuring the progress toward complete satisfaction of the performance obligation using a single method of measuring progress which depicts the performance in transferring control of the associated goods and/or services to the customer. The Company uses input methods to measure the progress toward the complete satisfaction of performance obligations satisfied over time. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. Any such adjustments are recorded on a cumulative catch-up As it relates to the Ares Trading Agreement (see Note 6), the Company recognized the upfront payment associated with its one open contract as a contract liability upon receipt of payment as it requires deferral of revenue recognition to a future period until the Company performs its obligations under the arrangement. Amounts expected to be recognized as revenue within the twelve months following the balance sheet date are classified in current liabilities. Amounts not expected to be recognized as revenue within the twelve months following the balance sheet date are classified as contract liabilities, net of current portion. The Company determined that there were three performance obligations; the first performance obligation consists of the license and research development services and the other two performance obligations are material rights as it relates to potential future targets that have not yet been identified. As described above, the transaction price of $57.5 million was allocated to the performance obligations based on their relative standalone selling prices. There are multiple distinct performance obligations, including material rights; thus, the Company allocates the transaction price to each distinct performance obligation based on its relative standalone selling price. The standalone selling price is generally determined based on the prices charged to customers or using expected cost plus margin. Revenue is recognized by measuring the progress toward complete satisfaction of the performance obligations using an input measure. Furthermore, the Company has not capitalized any contract costs under the guidance in ASC 340-40, Other Assets and Deferred Costs: Contracts with Customers The Company does not believe that any variable consideration should be included in the transaction price at the date of adoption of ASC 606 on January 1, 2018 or for the period ended September 30, 2018. Such assessment considered the application of the constraint to ensure that estimates of variable consideration would be included in the transaction price only to the extent the Company had a high degree of confidence that revenue would not be reversed in a subsequent reporting period. The Company will re-evaluate The first performance obligation includes three initial targets, two of which were substantially complete at March 31, 2018. Revenue recognized to date relates to these two targets. There is no remaining contract liability related to these two targets. The third target included in the first performance obligation has not yet been identified; revenue recognition will be deferred until the time that the work on the project begins. No revenue has been recognized related to the material rights, as the option for the material rights has not yet been exercised. The Company has classified the remaining contract liability of $49.5 million as current at September 30, 2018 as all remaining performance obligations are expected to be met in the fourth quarter of 2018, as a result of our License Agreement signed with Precigen subsequent to the balance sheet date (Note 1). As a result of adopting ASC 606, the Company recorded an $8.1 million adjustment to the opening balance of accumulated deficit in the first quarter of 2018 as a result of the treatment of the up-front 605-25 Impact of Topic 606 Adoption on the Balance Sheet ($ in thousands) as of January 1, 2018 Description As reported under Adjustments Balances without Contract liability, current portion $ 622 $ (5,767 ) $ 6,389 Contract liability, net of current portion $ 49,037 $ 13,898 $ 35,139 Accumulated deficit $ (720,573 ) $ (8,131 ) $ (712,442 ) The amount by which each financial statement line item is affected in the current reporting period by ASC 606 as compared with the guidance that was in effect prior to adoption is disclosed below. Impact of Topic 606 Adoption on the Balance Sheet ($ in thousands) as of September 30, 2018 Description As reported under Adjustments Balances without Contract liability, current portion $ 49,513 $ 12,777 $ 36,736 Accumulated deficit $ (761,209 ) $ 12,777 $ (748,432 ) Impact of Topic 606 Adoption on the Statement of Operations ($ in thousands) for the Three Months Ended September 30, 2018 Description As reported under Adjustments Balances without Collaboration revenue $ — $ (1,597 ) $ 1,597 Net loss $ (12,585 ) $ (1,597 ) $ (10,988 ) Basic and diluted net loss per share $ (0.13 ) $ (0.01 ) $ (0.12 ) Impact of Topic 606 Adoption on the Statement of Operations ($ in thousands) for the Nine Months Ended September 30, 2018 Description As reported under Adjustments Balances without Collaboration revenue $ 146 $ (4,646 ) $ 4,792 Net loss $ (40,636 ) $ (4,646 ) $ (35,990 ) Basic and diluted net loss per share $ (0.41 ) $ (0.04 ) $ (0.37 ) Impact of Topic 606 Adoption on the Statement of Cash Flows ($ in thousands) for the Nine Months Ended September 30, 2018 Description As reported under Adjustments Balances without Net loss $ (40,636 ) $ (4,646 ) $ (35,990 ) Changes in contract liability $ — $ 4,792 $ (4,792 ) The most significant change above relates to the Company’s collaboration revenue, which to date has been exclusively generated from its collaboration arrangement with Ares Trading and Precigen, formerly Intrexon (see Note 6). Under ASC 605, the Company accounted for the up-front

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2018
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	6. Commitments and Contingencies Operating Leases Prior to December 31, 2012, the Company entered into an operating lease in New York, NY for office space. In accordance with this agreement, the Company entered into a letter of credit in the amount of $388 thousand, naming the Company’s landlord as beneficiary. In January 2012, the Company amended the lease agreement, adding additional office space. The collateral for the letter of credit is restricted cash and recorded in other current assets on the balance sheet as of September 30, 2018. The lease for office space in New York, NY expires in October 2018. On October 17, 2013, the Company entered into a sublease agreement to lease all of its New York office space to a subtenant. The Company remains primarily liable to pay rent on the original lease. The Company recorded a loss on the sublease in the amount of $729 thousand for the year ended December 31, 2013, representing the remaining contractual obligation of $2.3 million, less $1.6 million in payments from its subtenant. Total sublease loss was approximately $31 thousand for each of the three-month periods ending September 30, 2018 and 2017. The Company continues to maintain the $388 thousand letter of credit in respect of the New York office space, which is recorded in other current assets on the balance sheet. Prior to December 31, 2012, the Company entered into separate operating lease agreements for various spaces in a building in Boston, MA. In June 2012, the Company re-negotiated On January 30, 2018, the Company entered into a lease agreement for office space in Houston, TX at MD Anderson. Under the terms of the Houston lease agreement, the Company leases approximately two hundred and ten square feet and is required to make rental payments at an average monthly rate of approximately $1 thousand through April 2021. Upon signing the lease agreement, the Company expensed approximately $40 thousand for rent expense for the period beginning in May 2015 through December 2017. The $40 thousand for rent expense incurred from May 2015 through December 2017, and all future rent expense incurred in Houston, are being deducted from our prepayment at MD Anderson described in the license agreement section below. Total rent expense was approximately $145 thousand and $534 thousand for the three and nine months ended September 30, 2018, respectively. Total rent expense was approximately $177 thousand and $545 thousand for the three and nine months ended September 30, 2017, respectively. The Company records rent expense on a straight-line basis over the term of the lease. Accordingly, the Company has recorded a liability for deferred rent at September 30, 2018 and December 31, 2017 of $30 thousand ($24 thousand as is classified current and $6 thousand as is classified long-term) and $142 thousand ($141 thousand as is classified current and $1 thousand as is classified long-term), respectively, which is recorded in deferred rent on the balance sheets. License Agreements Exclusive Channel Partner Agreement with Precigen for the Cancer Programs On January 6, 2011, the Company entered into the Channel Agreement with Intrexon (which Intrexon subsequently assigned to Precigen), that governs a “channel partnering” arrangement in which the Company uses Precigen’s technology to research, develop and commercialize products in which DNA is administered to humans for expression of anti-cancer effectors for treatment or prophylaxis of cancer, which the Company collectively refers to as the Cancer Program. This Channel Agreement established committees comprising representatives of us and Precigen that governed activities related to the Cancer Program in the areas of project establishment, chemistry, manufacturing and controls, clinical and regulatory matters, commercialization efforts and intellectual property. The Channel Agreement grants the Company a worldwide license to use patents and other intellectual property of Precigen in connection with the research, development, use, importing, manufacture, sale, and offer for sale of products involving DNA administered to humans for expression of anti-cancer effectors for the purpose of treatment or prophylaxis of cancer, which are collectively referred to as the Ziopharm Products. Such license is exclusive with respect to any clinical development, selling, offering for sale or other commercialization of Ziopharm Products, and otherwise is non-exclusive. Under the Channel Agreement, and subject to certain exceptions, the Company was responsible for, among other things, the performance of the Cancer Program, including the development, commercialization and certain aspects of manufacturing of Ziopharm Products. Precigen is responsible for establishing manufacturing capabilities and facilities for the bulk manufacture of products developed under the Cancer Program, certain other aspects of manufacturing and costs of discovery-stage research with respect to platform improvements and costs of filing, prosecution and maintenance of Precigen’s patents. After the 2016 ECP Amendment, discussed below, and subject to certain expense allocations and other offsets provided in the Channel Agreement, the Company was obligated to pay Precigen on a quarterly basis 20% of net profits derived in that quarter from the sale of Ziopharm Products, calculated on a Ziopharm Product-by-Ziopharm As discussed further in Note 1, on October 5, 2018, the Company entered into the License Agreement, the terms of which replace the terms of the Channel Agreement. Amendment of Collaborations with Precigen On March 27, 2015, the Company, together with Intrexon, (which Intrexon subsequently assigned to Precigen, Inc.), entered into an ECP Amendment, amending the Channel Agreement. The ECP Amendment modified the scope of the parties’ collaboration under the Channel Agreement in connection with the Ares Trading Agreement discussed below. Pursuant to the ECP Amendment, the chimeric antigen receptor T-cell On June 29, 2016, the Company entered into (1) the 2016 ECP Amendment with Precigen, amending the Channel Agreement, and (2) the 2016 GvHD Amendment, amending the GvHD Agreement. The 2016 ECP Amendment reduced the royalty percentage that the Company was able to pay to Precigen under the Channel Agreement on a quarterly basis from 50% to 20% of net profits derived in that quarter from the sale of Ziopharm Products, calculated on a Ziopharm Product-by-Ziopharm In consideration for the execution and delivery of the 2016 ECP Amendment and the 2016 GvHD Amendment, the Company agreed to issue to Intrexon 100,000 shares of its Series 1 preferred stock. Each share of Series 1 preferred stock has a stated value of $1,200, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization, and certain other rights, preferences, privileges and obligations (see Notes 1 and 9). As discussed further in Note 1, on October 5, 2018, the Company entered into the License Agreement, the terms of which replace the terms of the Channel Agreement. Exclusive Channel Collaboration Agreement with Precigen for GvHD On September 28, 2015, the Company entered into the GvHD Agreement with Intrexon (which Intrexon subsequently assigned to Precigen) whereby the Company would use Precigen’s technology directed towards in vivo The Company paid Intrexon a technology access fee of $10.0 million in cash in October 2015 and agreed to reimburse Intrexon for all related research and development costs pursuant to the GvHD Agreement. The Company has determined that the rights acquired in the GvHD Agreement represent in-process As a result of an in-depth License Agreement—The University of Texas MD Anderson Cancer Center On January 13, 2015, the Company, together with Intrexon (which Intrexon subsequently assigned to Precigen), entered into the MD Anderson License, with MD Anderson. Pursuant to the MD Anderson License, the Company, together with Precigen, hold an exclusive, worldwide license to certain technologies owned and licensed by MD Anderson including technologies relating to novel CAR T-cell non-viral co-exclusive non-exclusive Pursuant to the terms of the MD Anderson License, MD Anderson received consideration consisting of $50.0 million in shares of common stock (or 10,124,561 shares), and $50.0 million in shares of Intrexon’s common stock, in each case based on a trailing 20 day volume weighted average of the closing price the Company’s and Intrexon’s common stock ending on the date prior to the announcement of the entry into the MD Anderson License, collectively referred to as the License Shares. The License Shares were issued to MD Anderson on March 11, 2015, pursuant to the terms of the MD Anderson License. On January 9, 2015, in order to induce MD Anderson to enter into the MD Anderson License on an accelerated schedule, the Company, together with Intrexon entered into a letter agreement, or the Letter Agreement, pursuant to which MD Anderson received consideration of $7.5 million in shares of common stock (or 1,597,602 shares), and $7.5 million in shares of Intrexon’s common stock, in each case based on a trailing 20-day On August 17, 2015, the Company, Precigen and MD Anderson entered into the Research and Development Agreement, to formalize the scope and process for the transfer by MD Anderson, pursuant to the terms of the MD Anderson License, of certain existing research programs and related technology rights, as well as the terms and conditions for future collaborative research and development of new and ongoing research programs. Pursuant to the Research and Development Agreement, the Company, Precigen and MD Anderson have agreed to form a joint steering committee that will oversee and manage the new and ongoing research programs. As provided under the MD Anderson License, the Company provided funding for research and development activities in support of the research programs under the Research and Development Agreement for a period of three years and in an amount of no less than $15.0 million and no greater than $20.0 million per year. During the nine months ended September 30, 2018, the Company made payments in the aggregate amount of $2.7 million to MD Anderson compared to $9.3 million during the nine months ended September 30, 2017. The decrease in cash paid to MD Anderson during the nine months ended September 30, 2018 as compared to the same period in the prior year is a result of the final quarterly payment being made to MD Anderson in January 2018 and the result of approved expenditures incurred by us being deducted from the January 2018 quarterly payment. As of September 30, 2018, MD Anderson had used $11.4 million in program related expenses and reimbursed the company $3.7 million related to third party passthrough costs to offset of the prepaid balance for the MD Anderson License and the Research and Development Agreement. The net balance of cash resources on hand at MD Anderson available to offset expenses and future costs is $29.6 million, of which $11.5 million is included in other current assets and the remaining $18.1 million is included in non-current The term of the MD Anderson License expires on the last to occur of (a) the expiration of all patents licensed thereunder, or (b) the twentieth anniversary of the date of the MD Anderson License; provided, however, that following the expiration of the term of the MD Anderson License, the Company, together with Precigen, shall then have a fully-paid up, royalty free, perpetual, irrevocable and sublicensable license to use the licensed intellectual property thereunder. After ten years from the date of the MD Anderson License and subject to a 90-day non-exclusive case-by-case 180-day The Company determined that the rights acquired in the MD Anderson License represented in process research and development with no alternative future use. Accordingly, the Company recorded a charge of $67.3 million to research and development expense in 2015, representing the fair value of the 11,722,163 shares of its common stock on the date the MD Anderson License was executed. Ares Trading License and Collaboration Agreement On March 27, 2015, the Company, together with Intrexon (which Intrexon subsequently assigned to Precigen) and Ares Trading, signed the Ares Trading Agreement, through which the parties established a collaboration for the research and development and commercialization of certain products for the prophylactic, therapeutic, palliative or diagnostic use for cancer in humans. Under the collaboration, Ares Trading has elected two CAR + T-cell Precigen is entitled to receive $5.0 million from Ares Trading payable in equal quarterly installments over two years for each identified product candidate, which will be used to fund discovery work. The Company was responsible for costs exceeding the quarterly installments and all other costs of the preclinical research and development. For the three and nine months ended September 30, 2018, the Company has expensed $36 thousand under the Ares Trading Agreement. Ares Trading paid a non-refundable The Ares Trading Agreement provides for up to $60.0 million in development milestone payments, up to $148.0 million in regulatory milestone payments and up to $205.0 million in commercial milestone payments for each product candidate. Development milestone payments are triggered upon initiation of a defined phase of clinical research for a product candidate. Regulatory milestone payments are triggered upon approval to market a product candidate by the U.S. Food and Drug Administration (FDA), or other global regulatory authorities. Commercial milestone payments are triggered when an approved pharmaceutical product reaches certain levels of net sales defined in the license. The Ares Trading Agreement also provides for up to $50.0 million of one-time low-teens The term of the Ares Trading Agreement commenced in May 2015 and may be terminated by either party in the event of a material breach as defined in the agreement and may be terminated voluntarily by Ares Trading upon 90 days written notice to the Company. As discussed further in Note 1, on October 5, 2018, the Company entered into the License Agreement, the terms of which replace certain rights and obligations under the Ares Trading Agreement. See Note 5 for detail of the accounting for the Ares Trading Agreement. Patent and Technology License Agreement—The University of Texas MD Anderson Cancer Center and the Texas A&M University System On August 24, 2004, the Company entered into a patent and technology license agreement with MD Anderson and the Texas A&M University System, which the Company refers to, collectively, as the Licensors. Under this agreement, the Company was granted an exclusive, worldwide license to rights (including rights to U.S. and foreign patent and patent applications and related improvements and know-how) The Company issued to the licensors options to purchase 50,222 shares outside of its stock option plans following the successful completion of certain clinical milestones, of which 37,666 shares have vested. The remaining 12,556 shares vested upon enrollment of the first patient in a multi-center pivotal clinical trial. An expense of $87 thousand was charged to research and development expense for the vesting event which occurred in March 2016. This trial was initiated by Solasia Pharma K.K., or Solasia, on March 28, 2016 and triggered a $1.0 million milestone payment to the Company from Solasia which was received in May 2016. An equivalent of $1.0 million milestone payment was subsequently made to MD Anderson and reported net. The Licensors are entitled to receive certain milestone payments. In addition, the Company may be required to make additional payments to the Licensors (as defined in the MD Anderson License) upon achievement of certain other milestones in varying amounts which, on a cumulative basis could total up to an additional $4.5 million. In addition, the Licensors are entitled to receive single digit percentage royalty payments on sales from a licensed product and will also be entitled to receive a portion of any fees that the Company may receive from a possible sublicense under certain circumstances. Collaboration Agreement with Solasia Pharma K.K. On March 7, 2011, the Company entered into a License and Collaboration Agreement with Solasia, or the License and Collaboration Agreement. Pursuant to the License and Collaboration Agreement, the Company granted Solasia an exclusive license to develop and commercialize darinaparsin in both intravenous and oral forms and related organic arsenic molecules, in all indications for human use in a pan-Asian/Pacific As consideration for the license, the Company received an upfront payment of $5.0 million to be used exclusively for further clinical development of darinaparsin outside of the pan-Asian/Pacific On July 31, 2014, the Company entered into an amendment and restatement of the License and Collaboration Agreement granting Solasia an exclusive worldwide license to develop and commercialize darinaparsin, and related organoarsenic molecules, in both intravenous and oral forms in all indications for human use. In exchange, the Company will be eligible to receive from Solasia development- and sales-based milestones, a royalty on net sales of darinaparsin, once commercialized, and a percentage of any sublicense revenues generated by Solasia. Solasia will be responsible for all costs related to the development, manufacturing and commercialization of darinaparsin. The Company’s Licensors, as defined in the agreement, will receive a portion of all milestone and royalty payments made by Solasia to us in accordance with the terms of the license agreement with the Licensors. On March 28, 2016, Solasia initiated a multi-center pivotal clinical trial intended to provide substantial evidence of efficacy necessary to support the filing of an application for a New Drug Application, or NDA, for darinaparsin in certain of the territories assigned to Solasia. The initiation of the trial on March 28, 2016 triggered a $1.0 million milestone payment from Solasia to the Company which was received in May 2016. The Company subsequently made an equivalent payment to MD Anderson as the ultimate licensor of darinaparsin (see above). License Agreement with Baxter Healthcare S.A. On November 3, 2006, the Company entered into a definitive Asset Purchase Agreement for indibulin and a License Agreement to proprietary nanosuspension technology with affiliates of Baxter Healthcare S.A. The purchase included the entire indibulin intellectual property portfolio as well as existing drug substance and capsule inventories. The final royalty payment of $250 thousand was paid in November 2017. The terms of the Asset Purchase Agreement included an upfront cash payment and an additional payment for existing inventory. No payments were made during the three and nine months ended September 30, 2018 and 2017. Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute On January 10, 2017, the Company announced the signing of a Cooperative Research and Development Agreement, or CRADA, with the National Cancer Institute, or NCI, for the development of adoptive cell transfer, or ACT,-based immunotherapies genetically modified using the Sleeping Beauty non-viral SB-engineered

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2018
Related Party Transactions [Abstract]
Related Party Transactions	7. Related Party Transactions Collaborations with Intrexon/ Precigen On January 6, 2011, the Company entered into the Channel Agreement with Intrexon (which Intrexon subsequently assigned to Precigen), (see Note 6). Randal J. Kirk was a director of the Company until October 5, 2018. Mr. Kirk is the chief executive officer, a director, and the largest stockholder of Intrexon. On February 3, 2015, Intrexon purchased 1,440,000 shares of common stock in the Company’s public offering upon the same terms as others that participated in the offering. On March 27, 2015, the Company and Precigen entered into a Second Amendment to the Exclusive Channel Partner Agreement amending the Channel Agreement, which is referred to as the ECP Amendment. The ECP Amendment modified the scope of the parties’ collaboration under the Channel Agreement in connection with the Ares Trading Agreement, which the Company and Precigen entered into with Ares Trading, on March 27, 2015. The ECP Amendment provided that Precigen will pay to the Company 50% of all payments that Precigen receives for upfronts, milestones and royalties under the Ares Trading Agreement (see Note 6). The Amendment also reduces Precigen’s aggregate commitment under a Stock Purchase Agreement that the parties executed in connection with the initial Channel Agreement to purchase the Company’s common stock from $50.0 million to $43.5 million, which has been satisfied. On June 29, 2015, the Company re-purchased re-purchased On September 28, 2015, the Company entered into the GvHD Agreement with Intrexon (which Intrexon subsequently assigned to Precigen), whereby the Company was granted the right to use Precigen’s technology directed towards in vivo On June 29, 2016, the Company entered into the 2016 ECP Amendment, with Intrexon (which Intrexon subsequently assigned to Precigen), amending the Channel Agreement, and the 2016 GvHD Amendment, amending the GvHD Agreement. The 2016 ECP Amendment reduced the royalty percentage that the Company will pay to Precigen under the Channel Agreement on a quarterly basis from 50% to 20% of net profits derived in that quarter from the sale of Ziopharm Products (as defined in the Channel Agreement), calculated on a Ziopharm Product-by-Ziopharm In consideration for the execution and delivery of the 2016 ECP Amendment and the 2016 GvHD Amendment, the Company issued Intrexon 100,000 shares of its Series 1 preferred stock. Each share of the Company’s Series 1 preferred stock has a stated value of $1,200, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization, and certain other rights, preferences, privileges and obligations (see Note 9). The holders of the shares of Series 1 preferred stock are entitled to receive a monthly dividend, payable in additional shares of Series 1 preferred stock, equal to $12.00 per preferred share held by such holder per month divided by the stated value of the preferred shares, rounded down to the nearest whole share (see Note 9). During the three months ended September 30, 2018, the Company issued an aggregate of 3,847 shares of Series 1 preferred stock to Intrexon, the holder of all of the outstanding shares of the Company’s Series 1 preferred stock, as monthly dividend payments. At September 30, 2018, the Company recorded such shares of Series 1 preferred stock at a fair value of $6.1 million which is a component of temporary equity. During the three months ended September 30, 2018, the Company recorded a loss on the change of the derivative liabilities in the amount of $165 thousand. See Notes 9 and 10 for additional discussion regarding the accounting for and valuation of these derivative financial instruments. During the three months ended September 30, 2018, and 2017, the Company expensed $2.0 million and $5.6 million, respectively, for services performed by Precigen. During the nine months ended September 30, 2018, and 2017, the Company expensed $6.7 million and $16.8 million, respectively, for services performed by Precigen. As of September 30, 2018, and 2017, the Company recorded $2.9 million and $5.5 million, respectively, in current liabilities on its balance sheet for amounts due to Precigen. As discussed further in Note 1, on October 5, 2018, the Company entered into the License Agreement, the terms of which replace the terms of the Channel Agreement. Collaboration with Precigen and MD Anderson On January 13, 2015, the Company, together with Precigen, entered into the MD Anderson License. Pursuant to the MD Anderson License, the Company and Precigen hold an exclusive, worldwide license to certain technologies owned and licensed by MD Anderson, including technologies relating to novel CAR + T-cell co-exclusive non-exclusive in-process

Stock-Based Compensation

Stock-Based Compensation	9 Months Ended
	Sep. 30, 2018
Text Block [Abstract]
Stock-Based Compensation	8. Stock-Based Compensation The Company recognized stock-based compensation expense on all employee and non-employee For the three months ended September 30, For the nine months ended September 30, (in thousands) 2018 2017 2018 2017 Research and development $ 552 $ 615 $ 1,765 $ 1,772 General and administrative 928 1,467 5,085 4,393 Stock-based compensation expense $ 1,480 $ 2,082 $ 6,850 $ 6,165 The Company granted an aggregate of 300,500 and 506,000 stock options during the three and nine months ended September 30, 2018 with a weighted-average grant date fair value of $2.11 and $2.49 per share, respectively. The Company granted an aggregate of 593,500 and 859,000 stock options during the three and nine months ended September 30, 2017 with a weighted-average grant date fair value of $4.29 and $4.34 per share, respectively. On February 15, 2018, the Company extended the contractual life of 751,667 fully vested stock options held by one officer of the Company by an additional 9 months. Additionally, on March 12, 2018, the Company extended the contractual life of 117,500 fully vested stock options held by a director. These extensions resulted in additional stock-based compensation expense of $481 thousand in the nine months ended September 30, 2018. On September 18, 2018, the Company extended the contractual life of 92,500 fully vested stock options held by a director of the Company by approximately 9 months and 167,500 fully vested stock options held by another director of the Company by approximately 21 months. These extensions resulted in additional stock-based compensation expense of $117 thousand in the three and nine months ended September 30, 2018. Furthermore, the Company accelerated the vesting of 34,516 shares of restricted stock and recorded an adjustment of ($12) thousand in the three and nine months ended September 30, 2018. The Company recognizes forefeitures as they occur. For the three months ended September 30, 2018 and 2017, the fair value of stock options was estimated on the date of grant using a Black-Scholes option valuation model with the following assumptions: For the three months ended September 30, 2018 2017 Risk-free interest rate 2.82 - 2.98% 1.88 - 2.01% Expected life in years 6 6 Expected volatility 82.27 - 83.08% 80.82 - 80.95% Expected dividend yield 0 0 Stock option activity under the Company’s stock option plan for the nine months ended September 30, 2018 is as follows: (in thousands, except share and per share data) Number of Weighted- Weighted- Aggregate Outstanding, December 31, 2017 3,852,135 $ 5.12 Granted 506,000 3.50 Exercised (104,167 ) 2.30 Cancelled (184,500 ) 5.77 Outstanding, September 30, 2018 4,069,468 $ 5.24 6.17 $ 576 Options exercisable, September 30, 2018 2,924,501 $ 5.13 4.98 $ 498 Options exercisable, December 31, 2017 2,925,502 $ 5.12 5.58 $ 1,152 Options available for future grant 5,053,295 At September 30, 2018, total unrecognized compensation costs related to unvested stock options outstanding amounted to $4.1 million. The cost is expected to be recognized over a weighted-average period of 1.55 years. In September 2017, the Company issued a stock option award as an inducement grant for the purchase of an aggregate of 500,000 shares of the Company’s common stock, outside of the 2012 Plan, at an exercise price of $6.19 per share. The inducement grant is excluded from the option activity table above. A summary of the status of unvested restricted stock for the nine months ended September 30, 2018 is as follows: Number of Shares Weighted-Average Grant Date Fair Value Non-vested, 1,808,559 $ 5.74 Granted — — Vested (573,340 ) 7.61 Cancelled (70,867 ) 5.07 Non-vested, 1,164,352 $ 4.85 At September 30, 2018, total unrecognized compensation costs related to unvested restricted stock outstanding amounted to $3.5 million. The cost is expected to be recognized over a weighted-average period of 1.48 years.

Preferred Stock

Preferred Stock	9 Months Ended
	Sep. 30, 2018
Equity [Abstract]
Preferred Stock	9. Preferred Stock The Company has 30,000,000 shares of preferred stock authorized, of which, 250,000 shares are designated as Series 1 preferred stock. On June 29, 2016, the Company entered into the 2016 ECP Amendment and 2016 GvHD Amendment with Intrexon (which Intrexon subsequently assigned to Precigen), (see Note 6). In consideration for the execution and delivery of the 2016 ECP Amendment and the 2016 GvHD Amendment, the Company issued to Intrexon 100,000 shares of its newly designated Series 1 preferred stock. Each share of the Company’s Series 1 preferred stock has a stated value of $1,200, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization. As discussed in Note 1, in consideration of the Company entering into the License Agreement, Intrexon forfeited and returned to the Company all shares of the Company’s Series 1 Preferred Stock held by or payable to Intrexon as of the date of the License Agreement. No shares of Series 1 Preferred Stock are currently outstanding as of the filing date of this Quarterly Report. The Series 1 preferred stock has the following rights and preferences and certain other rights, preferences, privileges and obligations. See Note 1 for discussion of subsequent transaction regarding Series 1 preferred stock. Conversion All shares of Series 1 preferred stock shall automatically convert into shares of common stock upon the public announcement of the first approval in the United States of (i) a Ziopharm Product under the Channel Agreement, (ii) a Product under the GvHD Agreement or (iii) a Product under the Ares Trading Agreement, which the Company refers to as the Conversion Event Date. On the second business day following the Conversion Event Date, each share of Series 1 preferred stock shall convert into a number of shares of common stock equal to the stated value of such Series 1 preferred stock, divided by the greater of (i) the volume weighted average closing price of common stock as reported by The Nasdaq Stock Market, LLC over the 20 trading days ending on the Conversion Event Date or (ii) $1.00 per share; however, without shareholder approval in accordance with the Nasdaq listing rules, the Company will not affect any conversion of the Series 1 preferred stock into shares of common stock in excess of 19.9% of the lesser of (i) the pre-transaction Dividends The Series 1 preferred stock provides for a monthly dividend, payable in additional shares of Series 1 preferred stock, equal to $12.00 per share, per month divided by the stated value per share, or the PIK Dividend; provided, that if any shares of Series 1 preferred stock are not converted on the Conversion Event Date (discussed below), then the rate of the PIK Dividend on all remaining unconverted shares of Series 1 preferred stock shall automatically increase from $12.00 to $24.00 per share, per month. Liquidation Preference In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company or a change of control or sale, lease transfer or exclusive license of all or substantially all of the Company’s assets prior to the conversion of the Series 1 preferred stock into shares of common stock, then the Series 1 preferred stock will participate in the proceeds of the transaction on a pro rata basis along with common stock, treating the Series 1 preferred stock as if it had been converted into a number of shares of common stock equal to the aggregate stated value of the Series 1 preferred stock, divided by the volume weighted average closing price of common stock over the 20 trading days ending on the public announcement of such voluntary or involuntary liquidation, dissolution or winding up of the Company or change of control or sale, lease transfer or exclusive license of all or substantially all of the Company’s assets. Alternatively, the Company may redeem the Series 1 preferred stock at a redemption price equal to the pro rata amount that the Series 1 preferred stock would have received if it had been converted using the same formula. Voting Rights The Series 1 preferred stock does not have any voting rights except that the Company may not, without the consent of the holders of a majority of the outstanding shares of the Series 1 preferred stock, voting as a separate class, (i) amend, alter or repeal any provision of its Certificate of Incorporation in a manner that adversely affects the powers, preferences or rights of the Series 1 preferred stock in a manner that is more adverse than the effect on any other class or series of the Company’s capital stock; (ii) (A) create, or authorize the creation of, or issue or obligate itself to issue shares of, any additional class or series of the Company’s capital stock unless the same ranks junior or pari passu to the Series 1 preferred stock with respect to the distribution of assets on the liquidation, dissolution or winding up of the Company, the payment of dividends and rights of redemption, or (B) reclassify, alter or amend any existing security that is junior or pari passu to the Series 1 preferred stock with respect to the distribution of assets on the liquidation, dissolution or winding up of the Company, the payment of dividends or rights of redemption, if such reclassification, alteration or amendment would render such other security senior to the Series 1 preferred in respect of any such right, preference or privilege; or (iii) enter into any transaction (or series of related transactions) the effect of which would adversely affect the holders of the Series 1 preferred stock in a manner that is more adverse than the effect on any other class or series of capital stock. Analysis The Company analyzed the features of the Series 1 preferred stock and determined that the conversion option and the Company’s right to redeem the shares at liquidation are embedded derivatives that required bifurcation from the Series 1 preferred stock in accordance with FASB ASC 815, Derivatives and Hedging The fair value of the Series 1 preferred stock was estimated using a probability-weighted approach and a Monte Carlo simulation model. The fair value of the embedded derivatives was estimated using the “with” and “without” method where the preferred stock was first valued with all of its features (“with” scenario) and then without derivatives subject to the valuation analysis (“without” scenario). The fair value of the derivatives was then estimated as the difference between the fair value of the preferred stock in the “with” scenario and the preferred stock in the “without” scenario. The model also takes into account, management estimates of clinical success/failure based upon market studies and probability of potential conversion and liquidation events. If these estimates were different, the valuations would change, and that change could be material. Inputs to the models included the following: Risk-free interest rate 1.04 % Expected dividend rate 0 Expected volatility 70.50 % Preferred stock conversion limit - percentage of outstanding common stock 19.90 % Preferred conversion floor price $ 1.00 During the three and nine months ended September 30, 2018, the Company issued an aggregate of 3,847 shares and 11,205, shares of Series 1 preferred stock, respectively, to Intrexon, the holder of all of the outstanding shares of its Series 1 preferred stock, as monthly dividend payments. During the three and nine months ended September 30, 2018, the Company recorded such shares of Series 1 preferred stock at a fair value of $6.1 million and $16.7 million, respectively, which is a component of temporary equity. During the three and nine months ended September 30, 2018, the Company recorded a loss of $165 thousand and a gain of $46 thousand, respectively, on the change of the derivative liabilities (see Notes 1 and 10).

Derivative Financial Instrument

Derivative Financial Instruments	9 Months Ended
	Sep. 30, 2018
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Financial Instruments	10. Derivative Financial Instruments The Company determined that certain embedded features related to the Series 1 preferred stock are derivative financial instruments. Fair values of derivative instruments to be classified as derivative liabilities on the balance sheet consist of the following: ($ in thousands) Liability derivates: Balance Sheet Location Fair Value September 30, 2018: Derivative liabilities Liabilities $ 2,597 The change in the derivative liability for the nine months ended September 30, 2018 consisted of the following: ($ in thousands) Fair Value Balance, December 31, 2017 $ 2,424 Dividends 73 Change in fair value (28 ) Balance, March 31, 2018 $ 2,469 Dividends 72 Change in fair value (183 ) Balance, June 30, 2018 $ 2,358 Dividends 74 Change in fair value 165 Balance, September 30, 2018 $ 2,597 The fair value of the Series 1 preferred stock dividends was estimated using a probability-weighted approach and a Monte Carlo simulation model. The fair value of the embedded derivatives was estimated using the “with” and “without” method where the preferred stock was first valued with all of its features (“with” scenario) and then without derivatives subject to the valuation analysis (“without” scenario). The fair value of the derivatives was then estimated as the difference between the fair value of the preferred stock in the “with” scenario and the preferred stock in the “without” scenario. The model also takes into account, management estimates of clinical success/failure based upon market studies and probability of potential conversion and liquidation events. If these estimates were different, the valuations would change, and that change could be material. Inputs to the models included the following: September 30, 2018 December 31, 2017 Risk-free interest rate 2.97 % 1.92 - 2.12 % Expected dividend rate 0 0 Expected volatility 77.60 % 68.7 - 80.4 % Preferred stock conversion limit - percentage of outstanding common stock 19.90 % 19.90 % Preferred conversion floor price $ 1.00 $ 1.00 See Notes 1, 5, and 8 for additional discussion regarding the accounting for and valuation of these derivative financial instruments. As discussed in Note 1, in consideration of the Company entering into the License Agreement in October 2018, Intrexon has agreed to forfeit and return to the Company all shares of the Company’s Series 1 Preferred Stock held by or payable to Intrexon as of the date of the License Agreement. There are no other shares of Series 1 Preferred Stock outstanding as of the date of this Quarterly Report.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2018
Accounting Policies [Abstract]
New Accounting Pronouncements	New Accounting Pronouncements In February 2016, the FASB issued ASU No. 2016-02, Leases 2016-02. Leases In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows: Restricted Cash 2016-18. beginning-of-period end-of-period 2016-18 2016-18, September 30, 2018 2017 (in thousands) Cash and cash equivalents $ 31,728 $ 84,406 Restricted cash included in prepaid expenses and other current assets 389 — Restricted cash included in other non-current — 388 Total cash, cash equivalents, and restricted cash shown in the statement of cash flows $ 32,117 $ 84,794 In August 2018, the FASB issued ASU No. 2018-03, Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement 2018-03. In June 2018, the FASB issued ASU No. 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting 2018-07.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2018
Accounting Policies [Abstract]
Reconciliation of Cash, Cash Equivalents, and Restricted Cash	The following table provides a reconciliation of cash, cash equivalents, and restricted cash within the statement of financial position that sum to the total of the same such amounts shown in the statement of cash flows. September 30, 2018 2017 (in thousands) Cash and cash equivalents $ 31,728 $ 84,406 Restricted cash included in prepaid expenses and other current assets 389 — Restricted cash included in other non-current — 388 Total cash, cash equivalents, and restricted cash shown in the statement of cash flows $ 32,117 $ 84,794

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2018
Fair Value Disclosures [Abstract]
Assets and Liabilities Measured at Fair Value on Recurring Basis	Assets and liabilities measured at fair value on a recurring basis as of September 30, 2018 and December 31, 2017 were as follows: ($ in thousands) Fair Value Measurements at Reporting Date Using Description Balance as of Quoted Prices in Significant Other Significant Assets: Cash equivalents $ 30,305 $ 30,305 $ — $ — Liabilities: Derivative liabilities $ (2,597 ) $ — $ — $ (2,597 ) ($ in thousands) Fair Value Measurements at Reporting Date Using Description Balance as of Quoted Prices in Significant Other Significant Assets: Cash equivalents $ 66,156 $ 66,156 $ — $ — Liabilities: Derivative liabilities $ (2,424 ) $ — $ — $ (2,424 )

Net Loss per Share (Tables)

Net Loss per Share (Tables)	9 Months Ended
	Sep. 30, 2018
Earnings Per Share [Abstract]
Potential Dilutive Shares Excluded from Computation of Diluted Net Loss Per Share	Basic net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding for the period. The Company’s potentially dilutive shares, which include outstanding common stock options, unvested restricted stock and preferred stock, have not been included in the computation of diluted net loss per share for any of the periods presented as the result would be anti-dilutive. Such potentially dilutive shares of common stock at September 30, 2018 and 2017 consisted of the following: September 30, 2018 2017 Stock options 4,569,468 4,122,335 Unvested restricted stock 1,164,352 1,330,492 Preferred stock 52,583,921 22,398,582 58,317,741 27,851,409

Revenue Recognition (Tables)

Revenue Recognition (Tables)	9 Months Ended
	Sep. 30, 2018
ASU 2014-09
Impact of Topic 606 Adoption on Financial Statements	Refer below for a summary of the amount by which each financial statement line item was affected by the impact of the cumulative adjustment: Impact of Topic 606 Adoption on the Balance Sheet ($ in thousands) as of January 1, 2018 Description As reported under Adjustments Balances without Contract liability, current portion $ 622 $ (5,767 ) $ 6,389 Contract liability, net of current portion $ 49,037 $ 13,898 $ 35,139 Accumulated deficit $ (720,573 ) $ (8,131 ) $ (712,442 ) The amount by which each financial statement line item is affected in the current reporting period by ASC 606 as compared with the guidance that was in effect prior to adoption is disclosed below. Impact of Topic 606 Adoption on the Balance Sheet ($ in thousands) as of September 30, 2018 Description As reported under Adjustments Balances without Contract liability, current portion $ 49,513 $ 12,777 $ 36,736 Accumulated deficit $ (761,209 ) $ 12,777 $ (748,432 ) Impact of Topic 606 Adoption on the Statement of Operations ($ in thousands) for the Three Months Ended September 30, 2018 Description As reported under Adjustments Balances without Collaboration revenue $ — $ (1,597 ) $ 1,597 Net loss $ (12,585 ) $ (1,597 ) $ (10,988 ) Basic and diluted net loss per share $ (0.13 ) $ (0.01 ) $ (0.12 ) Impact of Topic 606 Adoption on the Statement of Operations ($ in thousands) for the Nine Months Ended September 30, 2018 Description As reported under Adjustments Balances without Collaboration revenue $ 146 $ (4,646 ) $ 4,792 Net loss $ (40,636 ) $ (4,646 ) $ (35,990 ) Basic and diluted net loss per share $ (0.41 ) $ (0.04 ) $ (0.37 ) Impact of Topic 606 Adoption on the Statement of Cash Flows ($ in thousands) for the Nine Months Ended September 30, 2018 Description As reported under Adjustments Balances without Net loss $ (40,636 ) $ (4,646 ) $ (35,990 ) Changes in contract liability $ — $ 4,792 $ (4,792 )

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2018
Text Block [Abstract]
Stock-Based Compensation Expense on All Employee and Non-Employee Awards	The Company recognized stock-based compensation expense on all employee and non-employee For the three months ended September 30, For the nine months ended September 30, (in thousands) 2018 2017 2018 2017 Research and development $ 552 $ 615 $ 1,765 $ 1,772 General and administrative 928 1,467 5,085 4,393 Stock-based compensation expense $ 1,480 $ 2,082 $ 6,850 $ 6,165
Fair Value of Stock Options Assumptions Using Black-Scholes Option Valuation Model	For the three months ended September 30, 2018 and 2017, the fair value of stock options was estimated on the date of grant using a Black-Scholes option valuation model with the following assumptions: For the three months ended September 30, 2018 2017 Risk-free interest rate 2.82 - 2.98% 1.88 - 2.01% Expected life in years 6 6 Expected volatility 82.27 - 83.08% 80.82 - 80.95% Expected dividend yield 0 0
Stock Option Activity under Stock Option Plan	Stock option activity under the Company’s stock option plan for the nine months ended September 30, 2018 is as follows: (in thousands, except share and per share data) Number of Weighted- Weighted- Aggregate Outstanding, December 31, 2017 3,852,135 $ 5.12 Granted 506,000 3.50 Exercised (104,167 ) 2.30 Cancelled (184,500 ) 5.77 Outstanding, September 30, 2018 4,069,468 $ 5.24 6.17 $ 576 Options exercisable, September 30, 2018 2,924,501 $ 5.13 4.98 $ 498 Options exercisable, December 31, 2017 2,925,502 $ 5.12 5.58 $ 1,152 Options available for future grant 5,053,295
Summary of Unvested Restricted Stock	A summary of the status of unvested restricted stock for the nine months ended September 30, 2018 is as follows: Number of Shares Weighted-Average Grant Date Fair Value Non-vested, 1,808,559 $ 5.74 Granted — — Vested (573,340 ) 7.61 Cancelled (70,867 ) 5.07 Non-vested, 1,164,352 $ 4.85

Derivative Financial Instrume_2

Derivative Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2018
Fair Value Assumptions Used in Probability Weighted Approach and Monte Carlo Simulation Model	The fair value of the Series 1 preferred stock was estimated using a probability-weighted approach and a Monte Carlo simulation model. The fair value of the embedded derivatives was estimated using the “with” and “without” method where the preferred stock was first valued with all of its features (“with” scenario) and then without derivatives subject to the valuation analysis (“without” scenario). The fair value of the derivatives was then estimated as the difference between the fair value of the preferred stock in the “with” scenario and the preferred stock in the “without” scenario. The model also takes into account, management estimates of clinical success/failure based upon market studies and probability of potential conversion and liquidation events. If these estimates were different, the valuations would change, and that change could be material. Inputs to the models included the following: Risk-free interest rate 1.04 % Expected dividend rate 0 Expected volatility 70.50 % Preferred stock conversion limit - percentage of outstanding common stock 19.90 % Preferred conversion floor price $ 1.00
Fair Values of Derivative Instruments to be classified as Derivative Liabilities on Balance Sheet	Fair values of derivative instruments to be classified as derivative liabilities on the balance sheet consist of the following: ($ in thousands) Liability derivates: Balance Sheet Location Fair Value September 30, 2018: Derivative liabilities Liabilities $ 2,597
Change in Derivative Liability	The change in the derivative liability for the nine months ended September 30, 2018 consisted of the following: ($ in thousands) Fair Value Balance, December 31, 2017 $ 2,424 Dividends 73 Change in fair value (28 ) Balance, March 31, 2018 $ 2,469 Dividends 72 Change in fair value (183 ) Balance, June 30, 2018 $ 2,358 Dividends 74 Change in fair value 165 Balance, September 30, 2018 $ 2,597
Series 1 Preferred Stock
Fair Value Assumptions Used in Probability Weighted Approach and Monte Carlo Simulation Model	The fair value of the Series 1 preferred stock dividends was estimated using a probability-weighted approach and a Monte Carlo simulation model. The fair value of the embedded derivatives was estimated using the “with” and “without” method where the preferred stock was first valued with all of its features (“with” scenario) and then without derivatives subject to the valuation analysis (“without” scenario). The fair value of the derivatives was then estimated as the difference between the fair value of the preferred stock in the “with” scenario and the preferred stock in the “without” scenario. The model also takes into account, management estimates of clinical success/failure based upon market studies and probability of potential conversion and liquidation events. If these estimates were different, the valuations would change, and that change could be material. Inputs to the models included the following: September 30, 2018 December 31, 2017 Risk-free interest rate 2.97 % 1.92 - 2.12 % Expected dividend rate 0 0 Expected volatility 77.60 % 68.7 - 80.4 % Preferred stock conversion limit - percentage of outstanding common stock 19.90 % 19.90 % Preferred conversion floor price $ 1.00 $ 1.00

Business - Additional Informati

Business - Additional Information (Detail) - USD ($) $ in Thousands	Oct. 05, 2018	Sep. 30, 2018	Jun. 30, 2018	Dec. 31, 2017	Sep. 30, 2017
Nature Of Operations [Line Items]
Accumulated deficit		$ (761,209)		$ (712,442)
Cash and cash equivalents		31,728		$ 70,946	$ 84,406
Intrexon Corporation/Precigen
Nature Of Operations [Line Items]
Transaction advisory expenses		$ 300	$ 1,000
Subsequent Event | Gorilla IL-12 Products
Nature Of Operations [Line Items]
Percentage of development cost shared by other party	80.00%
Percentage of operating profit shared by other party	80.00%
Subsequent Event | Intrexon Corporation/Precigen
Nature Of Operations [Line Items]
Reimbursement of historical costs	$ 1,000
Additional milestone payment for exclusively licensed program to be paid	52,500
Maximum Royalty payable	$ 100,000
Percentage of sublicensing income	20.00%
Royalty payment to be received	$ 100,000
Transaction advisory costs	7,000
Subsequent Event | Intrexon Corporation/Precigen | License
Nature Of Operations [Line Items]
Annual Licensing fee	$ 100
Subsequent Event | Intrexon Corporation/Precigen | Gorilla IL-12 Products
Nature Of Operations [Line Items]
Percentage of development cost shared by other party	20.00%
Percentage of operating profit shared by other party	20.00%

Reconciliation of Cash, Cash Eq

Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Detail) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017	Sep. 30, 2017	Dec. 31, 2016
Cash and Cash Equivalents [Abstract]
Cash and cash equivalents	$ 31,728	$ 70,946	$ 84,406
Restricted cash included in prepaid expenses and other current assets	389
Restricted cash included in other non-current assets			388
Total cash, cash equivalents, and restricted cash shown in the statement of cash flows	$ 32,117	$ 71,335	$ 84,794	$ 81,441

Assets and Liabilities Measured

Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - Fair Value, Measurements, Recurring - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	$ 30,305	$ 66,156
Derivative liabilities	(2,597)	(2,424)
Quoted Prices in Active Markets for Identical Assets/Liabilities (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	30,305	66,156
Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities	$ (2,597)	$ (2,424)

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Detail) - Intrexon Corporation/Precigen - Series 1 Preferred Stock - USD ($)	Jun. 29, 2016	Sep. 30, 2018	Sep. 30, 2018
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Issuance of stock in a license agreement (in shares)	100,000	3,847	11,205
Fair value measurement with unobservable inputs reconciliation liability transfers into level 3		$ 0	$ 0
Preferred stock, outstanding shares		0	0

Potential Dilutive Shares Exclu

Potential Dilutive Shares Excluded from Computation of Diluted Net Loss Per Share (Detail) - shares	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	58,317,741	27,851,409
Stock Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	4,569,468	4,122,335
Restricted Stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	1,164,352	1,330,492
Series 1 Preferred Stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	52,583,921	22,398,582

Net Loss per Share - Additional

Net Loss per Share - Additional Information (Detail) - Intrexon Corporation/Precigen - Series 1 Preferred Stock	9 Months Ended
	Sep. 30, 2018$ / sharesshares
Earnings Loss Per Share [Line Items]
Number of shares converted into common stock | shares	52,583,921
Preferred stock, conversion rate | $ / shares	$ 1

Revenue Recognition - Additiona

Revenue Recognition - Additional Information (Detail) - USD ($) $ in Thousands	Sep. 30, 2018	Jan. 01, 2018	Dec. 31, 2017	May 31, 2015
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Accumulated deficit	$ (761,209)		$ (712,442)
Remaining contract liability related to two targets expected to be recognized within the next twelve months	0
Contract liability, current portion	$ 49,513		$ 6,389
In Process Research and Development
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Estimated period of performance	9 years
ASU 2014-09
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Accumulated deficit		$ (720,573)
Contract liability, current portion		622
ARES Trading License
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Deferred revenue, upfront payment				$ 57,500
Difference between Revenue Guidance in Effect before and after Topic 606 | ASU 2014-09
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Accumulated deficit	$ 12,777	(8,131)
Contract liability, current portion	$ 12,777	$ (5,767)

Impact of Topic 606 Adoption on

Impact of Topic 606 Adoption on Financial Statements (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Jan. 01, 2018	Dec. 31, 2017
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Contract liability, current portion	$ 49,513		$ 49,513			$ 6,389
Contract liability, net of current portion						35,139
Accumulated deficit	(761,209)		(761,209)			$ (712,442)
Collaboration revenue			146
Net loss	$ (12,585)	$ (12,701)	$ (40,636)	$ (41,050)
Basic and diluted net loss per share	$ (0.13)	$ (0.13)	$ (0.41)	$ (0.41)
Net loss	$ (12,585)	$ (12,701)	$ (40,636)	$ (41,050)
Changes in contract liability			(146)	$ (4,792)
ASU 2014-09
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Contract liability, current portion					$ 622
Contract liability, net of current portion					49,037
Accumulated deficit					(720,573)
Difference between Revenue Guidance in Effect before and after Topic 606 | ASU 2014-09
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Contract liability, current portion	12,777		12,777		(5,767)
Contract liability, net of current portion					13,898
Accumulated deficit	12,777		12,777		$ (8,131)
Collaboration revenue	(1,597)		(4,646)
Net loss	$ (1,597)		$ (4,646)
Basic and diluted net loss per share	$ (0.01)		$ (0.04)
Net loss	$ (1,597)		$ (4,646)
Changes in contract liability			4,792
Calculated under Revenue Guidance in Effect before Topic 606 | ASU 2014-09
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Contract liability, current portion	36,736		36,736
Accumulated deficit	(748,432)		(748,432)
Collaboration revenue	1,597		4,792
Net loss	$ (10,988)		$ (35,990)
Basic and diluted net loss per share	$ (0.12)		$ (0.37)
Net loss	$ (10,988)		$ (35,990)
Changes in contract liability			$ (4,792)

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail)

Jun. 29, 2016$ / sharesshares

Sep. 28, 2015USD ($)

Jan. 13, 2015USD ($)shares

Jan. 09, 2015USD ($)shares

Mar. 07, 2011USD ($)

Jan. 06, 2011

Aug. 24, 2004Patent

Nov. 30, 2017USD ($)

May 31, 2016USD ($)

Sep. 30, 2015USD ($)

Jul. 31, 2015USD ($)

Sep. 30, 2018USD ($)$ / sharesshares

Mar. 31, 2018USD ($)

Sep. 30, 2017USD ($)

Sep. 30, 2018USD ($)$ / sharesshares

Sep. 30, 2017USD ($)

Dec. 31, 2015USD ($)shares

Dec. 31, 2013USD ($)

Dec. 31, 2012

Dec. 31, 2011USD ($)

Dec. 31, 2017USD ($)$ / shares

Jan. 30, 2018USD ($)ft²

Dec. 31, 2014USD ($)shares

Commitments and Contingencies Disclosure [Line Items]

Loss on sublease

$ 145,000

$ 177,000

$ 534,000

$ 545,000

$ 40,000

Deferred rent - current portion

24,000

24,000

141,000

Deferred rent-non-current portion

6,000

6,000

1,000

Deferred rent liability net

30,000

30,000

142,000

Research and Development Expense

8,263,000

11,105,000

25,935,000

33,903,000

Cash balance

$ 31,728,000

84,406,000

$ 31,728,000

84,406,000

$ 70,946,000

Series 1 Preferred Stock

Commitments and Contingencies Disclosure [Line Items]

Preferred stock, stated value | $ / shares

$ 1,200

$ 1,200

$ 1,200

Intrexon Corporation/Precigen | Series 1 Preferred Stock

Commitments and Contingencies Disclosure [Line Items]

Issuance of common stock in licensing agreement, shares | shares

100,000

3,847

11,205

Preferred stock, stated value | $ / shares

$ 1,200

ECP Channel Agreement | Intrexon Corporation/Precigen | Quarterly Payment

Commitments and Contingencies Disclosure [Line Items]

Royalty percentage of net profit

20.00%

Percentage of revenue agreed to pay which is obtained from sublicensor

50.00%

ECP Channel Agreement | Intrexon Corporation/Precigen | Quarterly Payment | After Amendment

Commitments and Contingencies Disclosure [Line Items]

Royalty percentage of net profit

20.00%

ECP Channel Agreement | Intrexon Corporation/Precigen | Quarterly Payment | Before Amendment

Commitments and Contingencies Disclosure [Line Items]

Royalty percentage of net profit

50.00%

2016 GvHD Amendment | Intrexon Corporation/Precigen

Commitments and Contingencies Disclosure [Line Items]

Research and Development Expense

$ 10,000,000

2016 GvHD Amendment | Intrexon Corporation/Precigen | Quarterly Payment | After Amendment

Commitments and Contingencies Disclosure [Line Items]

Royalty percentage of net profit

20.00%

2016 GvHD Amendment | Intrexon Corporation/Precigen | Quarterly Payment | Before Amendment

Commitments and Contingencies Disclosure [Line Items]

Royalty percentage of net profit

50.00%

2016 GvHD Amendment | Intrexon Corporation/Precigen | License

Commitments and Contingencies Disclosure [Line Items]

Licensing fee

$ 10,000,000

License Agreement | M.D. Anderson Cancer Center

Commitments and Contingencies Disclosure [Line Items]

Issuance of common stock in licensing agreement, shares | shares

11,722,163

11,722,163

Research and Development Expense

$ 67,300,000

$ 67,300,000

Common stock issued for cash | shares

10,124,561

Cash consideration for license agreement

$ 50,000,000

License Agreement | The University of Texas MD Anderson Cancer Center and The Texas A & M University System

Commitments and Contingencies Disclosure [Line Items]

Milestone maximum payment

$ 4,500,000

Number of products | Patent

2

Options to purchase common stock | shares

50,222

Shares vested | shares

37,666

License Agreement | The University of Texas MD Anderson Cancer Center and The Texas A & M University System | Research and Development Expense

Commitments and Contingencies Disclosure [Line Items]

Issuance of common stock in a license agreement

$ 87,000

License Agreement | The University of Texas MD Anderson Cancer Center and The Texas A & M University System | Upon enrollment of the first patient in a multi-center pivotal clinical trial

Commitments and Contingencies Disclosure [Line Items]

Shares vested | shares

12,556

License Agreement | Baxter Healthcare Corporation | Upon the successful U.S. IND application for indibulin

Commitments and Contingencies Disclosure [Line Items]

Installment payments

$ 250,000

$ 0

0

0

0

License Agreement | Intrexon Corporation/Precigen | M.D. Anderson Cancer Center

Commitments and Contingencies Disclosure [Line Items]

Cash consideration for license agreement

50,000,000

Letter Agreement | M.D. Anderson Cancer Center

Commitments and Contingencies Disclosure [Line Items]

Common stock issued for cash | shares

1,597,602

Cash consideration for license agreement

$ 7,500,000

Letter Agreement | Intrexon Corporation/Precigen | M.D. Anderson Cancer Center

Commitments and Contingencies Disclosure [Line Items]

Cash consideration for license agreement

$ 7,500,000

ARES Trading License

Commitments and Contingencies Disclosure [Line Items]

Research and Development Expense

36,000

$ 36,000

Agreement commencement date

2015-05

Agreement termination, notice period

90 days

ARES Trading License | Development Milestone Payments

Commitments and Contingencies Disclosure [Line Items]

Payments for development, regulatory and commercial milestones per product

$ 60,000,000

ARES Trading License | Regulatory Milestone Payments

Commitments and Contingencies Disclosure [Line Items]

Payments for development, regulatory and commercial milestones per product

148,000,000

ARES Trading License | Commercial Milestone Payments

Commitments and Contingencies Disclosure [Line Items]

Payments for development, regulatory and commercial milestones per product

205,000,000

ARES Trading License | Intrexon Corporation/Precigen

Commitments and Contingencies Disclosure [Line Items]

Milestone payment receivable

$ 5,000,000

Milestone payment receivable period

2 years

Upfront payment received

$ 57,500,000

Percentage of upfront fee payable

50.00%

Milestone maximum payment

50,000,000

$ 50,000,000

ARES Trading License | Intrexon Corporation/Precigen | Substantive Milestones

Commitments and Contingencies Disclosure [Line Items]

Potential milestone payment

15,000,000

15,000,000

ARES Trading License | Intrexon Corporation/Precigen | License

Commitments and Contingencies Disclosure [Line Items]

Licensing fee

$ 115,000,000

Collaboration Agreement | M.D. Anderson Cancer Center

Commitments and Contingencies Disclosure [Line Items]

Installment payments

$ 1,000,000

Collaboration Agreement | Solasia

Commitments and Contingencies Disclosure [Line Items]

Upfront payment received

$ 5,000,000

Milestone payment received

$ 1,000,000

Collaboration Agreement | Solasia | Development-based milestones

Commitments and Contingencies Disclosure [Line Items]

Expected additional milestone payments to be received

32,500,000

Collaboration Agreement | Solasia | Sales-based milestones

Commitments and Contingencies Disclosure [Line Items]

Expected additional milestone payments to be received

$ 53,500,000

Cooperative Research and Development Agreement

Commitments and Contingencies Disclosure [Line Items]

Research and development arrangement Terms

Pursuant to the Research and Development Agreement, the Company, Intrexon and MD Anderson have agreed to form a joint steering committee that will oversee and manage the new and ongoing research programs. As provided under the MD Anderson License, the Company will provide funding for research and development activities in support of the research programs under the Research and Development Agreement for a period of three years and in an amount of no less than $15.0 million and no greater than $20.0 million per year.

Cooperative Research and Development Agreement | Minimum

Commitments and Contingencies Disclosure [Line Items]

Research and Development Expense

15,000,000

Cooperative Research and Development Agreement | Maximum

Commitments and Contingencies Disclosure [Line Items]

Research and Development Expense

$ 20,000,000

Cooperative Research and Development Agreement | M.D. Anderson Cancer Center

Commitments and Contingencies Disclosure [Line Items]

Research and Development Service Agreement Payment

$ 2,700,000

$ 2,700,000

$ 9,300,000

Cooperative Research and Development Agreement | M.D. Anderson Cancer Center

Commitments and Contingencies Disclosure [Line Items]

Funding used to offset costs in research and development expense

11,400,000

Cash balance

29,600,000

29,600,000

Program related expenses being reimbursed

3,700,000

Cooperative Research and Development Agreement | M.D. Anderson Cancer Center | Prepaid Expenses and Other Current Assets

Commitments and Contingencies Disclosure [Line Items]

Cash balance

11,500,000

11,500,000

Cooperative Research and Development Agreement | M.D. Anderson Cancer Center | Other Noncurrent Assets

Commitments and Contingencies Disclosure [Line Items]

Cash balance

18,100,000

18,100,000

Cooperative Research and Development Agreement | Intrexon Corporation/Precigen | National Cancer Institute

Commitments and Contingencies Disclosure [Line Items]

Obligation for payment

3,100,000

3,100,000

Miles stone payment payable

625,000

625,000

Milestone payment paid

625,000

1,900,000

Houston, TX

Commitments and Contingencies Disclosure [Line Items]

Operating lease area | ft²

210

Operating leases future minimum monthly payment due through year 2021

$ 1,000

New York, NY

Commitments and Contingencies Disclosure [Line Items]

Letter of credit

388,000

388,000

$ 388,000

Operating lease expiration month and year

2018-10

Loss on sublease

$ 729,000

Obligation for payment

2,300,000

Sublease revenue from subtenant

$ 1,600,000

Loss on sublease

31,000

$ 31,000

Boston, MA

Commitments and Contingencies Disclosure [Line Items]

Operating lease expiration month and year

2016-08

Security deposits

$ 128,000

$ 128,000

Sublease term amendment

Aug. 31, 2021

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	Jun. 29, 2016	Jan. 08, 2016	Sep. 28, 2015	Jun. 29, 2015	Mar. 27, 2015	Feb. 03, 2015	Jan. 06, 2011	Sep. 30, 2015	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2015	Dec. 31, 2017
Related Party Transaction [Line Items]
Company re-purchased additional shares Value													$ 1,275
Change in fair value of derivative liability									$ (165)	$ 183	$ 28	$ 202	46	$ (1,292)
Research and Development Expense									$ 8,263			11,105	$ 25,935	33,903
Series 1 Preferred Stock
Related Party Transaction [Line Items]
Preferred stock, stated value									$ 1,200				$ 1,200			$ 1,200
Temporary equity, fair value									$ 6,100				$ 16,700
License Agreement | M.D. Anderson Cancer Center
Related Party Transaction [Line Items]
Issuance of common stock in licensing agreement (in shares)													11,722,163		11,722,163
Research and Development Expense													$ 67,300		$ 67,300
Cooperative Research and Development Agreement | M.D. Anderson Cancer Center
Related Party Transaction [Line Items]
Research and Development Service Agreement Quarterly Payment											2,700		2,700	9,300
Research and Development Service Agreement Aggregate Payments											$ 41,900
Intrexon Corporation/Precigen
Related Party Transaction [Line Items]
Stock issued during period						1,440,000
Percentage of commitment for payments from receipts of upfronts, milestones and royalties					50.00%
Commitment to purchase common stock					$ 43,500		$ 50,000
Stock buy back (Shares)				3,711
Stock buy back				$ 34
Share buy back discount on closing price				5.00%
Company re-purchased additional shares		168
Company re-purchased additional shares Value		$ 2
Amounts expensed for services incurred									2,000			5,600	6,700	16,800
Amount due to related party, current									$ 2,900			$ 5,500	$ 2,900	$ 5,500
Intrexon Corporation/Precigen | Series 1 Preferred Stock
Related Party Transaction [Line Items]
Issuance of common stock in licensing agreement (in shares)	100,000								3,847				11,205
Preferred stock, stated value	$ 1,200
Dividends, preferred stock	$ 12
Intrexon Corporation/Precigen | 2016 GvHD Amendment
Related Party Transaction [Line Items]
Research and Development Expense								$ 10,000
Intrexon Corporation/Precigen | 2016 GvHD Amendment | License
Related Party Transaction [Line Items]
Licensing fee			$ 10,000
Intrexon Corporation/Precigen | 2016 GvHD Amendment | Quarterly Payment | After Amendment
Related Party Transaction [Line Items]
Royalty percentage of net profit	20.00%
Intrexon Corporation/Precigen | 2016 GvHD Amendment | Quarterly Payment | Before Amendment
Related Party Transaction [Line Items]
Royalty percentage of net profit	50.00%
Intrexon Corporation/Precigen | ECP Channel Agreement | Quarterly Payment
Related Party Transaction [Line Items]
Royalty percentage of net profit							20.00%
Intrexon Corporation/Precigen | ECP Channel Agreement | Quarterly Payment | After Amendment
Related Party Transaction [Line Items]
Royalty percentage of net profit	20.00%
Intrexon Corporation/Precigen | ECP Channel Agreement | Quarterly Payment | Before Amendment
Related Party Transaction [Line Items]
Royalty percentage of net profit	50.00%

Stock-Based Compensation Expens

Stock-Based Compensation Expense Included in Statement of Operations (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation	$ 1,480	$ 2,082	$ 6,850	$ 6,165
Research and Development Expense
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation	552	615	1,765	1,772
General and Administrative Expense
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation	$ 928	$ 1,467	$ 5,085	$ 4,393

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	Sep. 18, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Mar. 12, 2018	Feb. 15, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options, granted			300,500	593,500	506,000	859,000
Weighted-average grant date fair value			$ 2.11	$ 4.29	$ 2.49	$ 4.34
Additional stock-based compensation expense					$ 481
Accelerated vested of restricted Shares	34,516
Adjustment of restricted vested amount			$ 12		$ 12
Stock options granted exercise price					$ 3.50
Director One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Extended contractual life	92,500
Director Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Extended contractual life	167,500
Director
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Extended contractual life							117,500
Additional stock-based compensation expense			117		$ 117
Officer
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Extended contractual life								751,667
Outside 2012 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options, granted		500,000
Stock options granted exercise price		$ 6.19
Unvested Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation costs related to unvested restricted stock outstanding			4,100		$ 4,100
Expected recognition period					1 year 6 months 18 days
Unvested Restricted Common Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected recognition period					1 year 5 months 23 days
Unrecognized stock-based compensation expense related to unvested restricted stock			$ 3,500		$ 3,500

Fair Value of Stock Options Ass

Fair Value of Stock Options Assumptions Using Black-Scholes Option Valuation Model (Detail)	3 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Risk-free interest rate, Minimum	2.82%	1.88%
Risk-free interest rate, Maximum	2.98%	2.01%
Expected life in years	6 years	6 years
Expected volatility, Minimum	82.27%	80.82%
Expected volatility, Maximum	83.08%	80.95%
Expected dividend yield	0.00%	0.00%

Stock Option Activity under Sto

Stock Option Activity under Stock Option Plan (Detail) - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Number of Shares
Beginning Balance	3,852,135
Granted	506,000
Exercised	(104,167)
Cancelled	(184,500)
Ending Balance	4,069,468	3,852,135
Options exercisable, at end of period	2,924,501	2,925,502
Options available for future grant	5,053,295
Weighted Average Exercise Price
Beginning Balance	$ 5.12
Granted	3.50
Exercised	2.30
Cancelled	5.77
Ending Balance	5.24	$ 5.12
Options exercisable, at end of period	$ 5.13	$ 5.12
Weighted Average Contractual Term (Years)
Outstanding, at end of period	6 years 2 months 1 day
Options exercisable, at end of period	4 years 11 months 23 days	5 years 6 months 29 days
Aggregate Intrinsic Value
Outstanding, at end of period	$ 576
Options exercisable, at end of period	$ 498	$ 1,152

Summary of Unvested Restricted

Summary of Unvested Restricted Stock (Detail) - Unvested Restricted Common Stock	9 Months Ended
	Sep. 30, 2018$ / sharesshares
Number of Shares
Beginning Balance | shares	1,808,559
Granted | shares	0
Vested | shares	(573,340)
Cancelled | shares	(70,867)
Ending Balance | shares	1,164,352
Weighted Average Grant Date Fair Value
Beginning Balance | $ / shares	$ 5.74
Granted | $ / shares	0
Vested | $ / shares	7.61
Cancelled | $ / shares	5.07
Ending Balance | $ / shares	$ 4.85

Preferred Stock - Additional In

Preferred Stock - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	Jun. 29, 2016	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017	Jul. 01, 2016
Preferred Stock [Line Items]
Preferred stock, shares authorized		30,000,000				30,000,000		30,000,000
Change in derivative liability		$ (165)	$ 183	$ 28	$ 202	$ 46	$ (1,292)
Series 1 Preferred Stock
Preferred Stock [Line Items]
Preferred stock, shares authorized		250,000				250,000		250,000
Preferred stock, stated value		$ 1,200				$ 1,200		$ 1,200
Maximum percentage of common stock issuable upon conversion of preferred stock						19.90%		19.90%
Fair value of Series 1 preferred stock as a component of temporary equity		$ 160,429				$ 160,429		$ 143,992
Temporary equity, fair value		6,100				16,700
Intrexon Corporation/Precigen
Preferred Stock [Line Items]
Embedded conversion liability		$ 900				$ 900
Fair value of Series 1 preferred stock as a component of temporary equity									$ 118,200
Intrexon Corporation/Precigen | Series 1 Preferred Stock
Preferred Stock [Line Items]
Preferred stock, shares issued	100,000	3,847				11,205
Preferred stock, stated value	$ 1,200
Preferred stock, outstanding shares		0				0
Preferred stock, conversion rate						$ 1
Maximum percentage of common stock issuable upon conversion of preferred stock						19.90%
Preferred stock monthly dividend payable (per share)	$ 12
Intrexon Corporation/Precigen | Series 1 Preferred Stock | Before Conversion Event Date
Preferred Stock [Line Items]
Preferred stock monthly dividend payable (per share)						$ 12
Intrexon Corporation/Precigen | Series 1 Preferred Stock | Remaining Unconverted Shares
Preferred Stock [Line Items]
Preferred stock monthly dividend payable (per share)						$ 24

Fair Value Assumptions Used in

Fair Value Assumptions Used in Probability Weighted Approach and Monte Carlo Simulation Model (Detail) - Series 1 Preferred Stock - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Preferred stock conversion limit - percentage of outstanding common stock	19.90%	19.90%
Preferred conversion floor price	$ 1	$ 1
Measurement Input, Risk Free Interest Rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair Value Assumptions of Preferred Stock	1.04%
Measurement Input, Expected Dividend Rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair Value Assumptions of Preferred Stock	0.00%	0.00%
Measurement Input, Price Volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair Value Assumptions of Preferred Stock	70.50%

Fair Values of Derivative Instr

Fair Values of Derivative Instruments to be classified as Derivative Liabilities on Balance Sheet (Detail) - USD ($) $ in Thousands	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017
Derivatives, Fair Value [Line Items]
Derivative liabilities	$ 2,597	$ 2,358	$ 2,469	$ 2,424
Liabilities
Derivatives, Fair Value [Line Items]
Derivative liabilities	$ 2,597

Change in Derivative Liability

Change in Derivative Liability (Detail) - USD ($) $ in Thousands	3 Months Ended				9 Months Ended
	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Beginning Balance	$ 2,358	$ 2,469	$ 2,424		$ 2,424
Dividends	74	72	73
Change in fair value of derivative liabilities	165	(183)	(28)	$ (202)	(46)	$ 1,292
Ending Balance	$ 2,597	$ 2,358	$ 2,469		$ 2,597

Fair Value Assumptions Used i_2

Fair Value Assumptions Used in Probability Weighted Approach and Monte Carlo Simulation Model for Derivatives (Detail) - Series 1 Preferred Stock - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Preferred stock conversion limit-percentage of outstanding common stock	19.90%	19.90%
Preferred conversion floor price	$ 1	$ 1
Measurement Input, Risk Free Interest Rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair Value Assumptions of Preferred Stock	1.04%
Measurement Input, Risk Free Interest Rate | Minimum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair Value Assumptions of Preferred Stock	2.97%	1.92%
Measurement Input, Risk Free Interest Rate | Maximum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair Value Assumptions of Preferred Stock		2.12%
Measurement Input, Expected Dividend Rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair Value Assumptions of Preferred Stock	0.00%	0.00%
Measurement Input, Price Volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair Value Assumptions of Preferred Stock	70.50%
Measurement Input, Price Volatility | Minimum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair Value Assumptions of Preferred Stock	77.60%	68.70%
Measurement Input, Price Volatility | Maximum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair Value Assumptions of Preferred Stock		80.40%

Derivative Financial Instrume_3

Derivative Financial Instruments - Additional Information (Detail)	Sep. 30, 2018shares
Intrexon Corporation/Precigen | Series 1 Preferred Stock
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Preferred stock, outstanding shares	0